( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57



Dr. Ntumba Kabasele Clemence, *Wang Xue Feng, Mark Momoh Koroma, Samson Kaphera


Objective: This paper which aimed at comparing clinical outcomes of Olaparib and Bev in women who developed ovarian carcinoma. These trials outcomes included, first Overall Survival second Progression free Survival then the third is development of Adverse Events. Methods: Search strategies: randomized trial AND (Olaparib OR bevacizumab) AND (peritoneal cancer OR tubal cancer OR ovarian cancer) all advanced search. There after, data were extracted data from selected studies. Data extracted was entered on Excel and thereafter exported to SPSS and R for analysis. We used three random models for three outcomes separately as stated in the objective section. Statistical fit tests were performed and analyzed. Results: BEV exhibited longer PFS than OLA although the statistic difference was not significant was not statistically (es, 4.360 ([95% CI] -1.335 - 10.055), p>.05 in Bev; 0.149 (95% CI -2.234 to 2.531) p>.05 in Ola). On the other hand, Ola significantly reduced OS as compared with Bev (es, -0.775 (95% CI -1.115 to 5.716) p<.001 in Ola and 1.199 ([95% CI ]-1.638 to 4.036) p>.05 in Bev.). Bev resulted into lower AEs than Ola although the modification was not significant according to statistics performed (es, 0.491 ([95% CI] -3.156 to 4.137), p>.05) in Ola and -0.035 (95% CI -4.880 to 4.809), p>.05). Limitations: Our study used data that were reported in other studies. This is because meta-analyses have secondary reliability because they depend on the level of accuracy and truthfulness of previous studies. Moreover, the study did not account for confounding variables including BRCA mutation; a fact that has the potential to reduce the strength of evidence. Conclusions: The study shows that Olaparib might be statistically effective at the same level of therapeutic approach with Bevacizumab with PFS and OS. Adverse events risk in Olaparib and bevacizumab are almost similar in cases with resistance to platinum, recurrent cancer, fallopian tube or peritoneal cancer.

Keywords: Ovarian cancer, Tubal cancer, Bevacizumab, Peritoneal cancer, Olaparib and randomized clinical trial.

[Full Text Article] [Download Certificate]


  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44



  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 July 2024 Issue has been Published, Kindly check it on


    JULY 2024 issue has been successfully launched on JULY 2024.

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia